Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 11/20 | 0.43 |
| ▸ | CDC42BPB | Q9Y5S2 | 11/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 10/20 | 0.43 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.43 |
| ▸ | CDC42BPA | Q5VT25 | 3/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.40 |
| ▸ | STK4 | Q13043 | 2/20 | 0.39 |
| ▸ | STK3 | Q13188 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14158643 | 0.86 | ROCK1 (0.46) | ROCK1CDC42BPBROCK2CDC42BPALRRK2 | |
| SCHEMBL14158681 | 0.85 | GAA (0.46) | GAAGLO1KDM4E | |
| SCHEMBL14242800 | 0.84 | LRRK2 (0.45) | ROCK1CDC42BPBROCK2CDC42BPALRRK2 | |
| SCHEMBL14158563 | 0.81 | STK4 (0.51) | ROCK1CDC42BPBROCK2CDC42BPALRRK2 | |
| SCHEMBL14158779 | 0.80 | LRRK2 (0.45) | ROCK1CDC42BPBROCK2CDC42BPALRRK2 | |
| SCHEMBL14158722 | 0.78 | LRRK2 (0.52) | LRRK2STK4STK3KDM4E | |
| SCHEMBL14157490 | 0.77 | HTR6 (0.54) | ROCK1CDC42BPB | |
| SCHEMBL14242746 | 0.75 | ROCK1 (0.48) | ROCK1CDC42BPBROCK2CDC42BPALRRK2 | |
| SCHEMBL14158918 | 0.72 | CYBB (0.55) | ROCK1CDC42BPBROCK2 | |
| SCHEMBL14243205 | 0.72 | ROCK1 (0.46) | ROCK1CDC42BPBROCK2CDC42BPALRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877742-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED (GB) | 2014-11-04 | — | — | US | disclosed |
| US-8877742-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED (GB) | 2014-11-04 | — | — | US | disclosed |
| US-8877742-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED (GB) | 2014-11-04 | — | — | US | disclosed |
| US-20140155375-A1 | NOVEL COMPOUNDS | GlaxoSmithKline Interllectual Property Limited (GB) | 2014-06-05 | — | — | US | disclosed |
| US-20140155375-A1 | NOVEL COMPOUNDS | GlaxoSmithKline Interllectual Property Limited (GB) | 2014-06-05 | — | — | US | disclosed |
| US-20140155375-A1 | NOVEL COMPOUNDS | GlaxoSmithKline Interllectual Property Limited (GB) | 2014-06-05 | — | — | US | disclosed |
| EP-2717694-A1 | NOVEL COMPOUNDS | GlaxoSmithKline Intellectual Property Limited (GB) | 2014-04-16 | — | — | EP | disclosed |
| WO-2012170752-A1 | NOVEL COMPOUNDS | GLAXO WELLCOME MANUFACTURING PTE LTD (SG) | 2012-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155375-A1 | NOVEL COMPOUNDS | CYBB, NOX1, NOX4 | GAA 546/4885ROCK1 852/4885CDC42BPB 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.